Introduction
Next generation sequencing has revealed activating MYD88 mutations in several B-cell malignancies. Particularly striking has been the expression of MYD88 mutations in Waldenstrom Macroglobulinemia (WM), wherein 95-97% of patients express MYD88 L265P , and more rarely non-L265P MYD88 mutations. [1] [2] [3] [4] Up to 30%
of patients with activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (ABC DLBCL) also express activating MYD88 mutations, including MYD88 L265P . 5, 6 Mutations in MYD88 promote Myddosome self-assembly and can trigger NF-kB signaling in the absence of Toll (TLR) or IL1 (IL1R) receptor signaling through IL1
Receptor Associated Kinases (IRAK4/IRAK1) or Bruton's Tyrosine Kinase (BTK). 5, 7 Ibrutinib is a pleiotropic kinase inhibitor that is known to target BTK, and is highly active in previously treated WM patients producing an overall response rate of 91%. 8 In WM patients, both major and overall responses to ibrutinib are higher in patients with MYD88 mutations. 9 CXCR4 WHIM mutations that are present in up to 40% of WM patients can also impact ibrutinib response. 4 Ibrutinib also shows activity in previously treated patients with ABC-DLBCL, particularly among patients with BCR pathway and MYD88 mutations. 10 Ibrutinib is also active in other B-cell malignancies including CLL and MCL. Suppression of tonic B-cell receptor (BCR) activity mediated by BTK has been implicated as the mechanism underlying ibrutinib activity in non-WM B-cell diseases.
In addition to BTK, ibrutinib can suppress the activity of several other kinases including members of the SRC family. 11 Hematopoietic cell kinase (HCK) is a member of the SRC family of protein tyrosine kinases, and one of the most aberrantly up-regulated genes in WM cells. 12 In myeloma cells, HCK is activated by interleukin 6 (IL6) through the IL6 co-receptor IL6ST (GP130). 13, 14 IL6 is also a potent growth and survival factor in WM, though the functional significance of HCK in WM pathogenesis remains unclear. 15 We therefore investigated the role of HCK in WM, and impact of MYD88 mutations and ibrutinib on the transcriptional regulation and activation of this SRC family member.
Materials and Methods

Primary cells and cell lines
Primary WM cells (CD19 + ) were isolated from bone marrow (BM) aspirates, and peripheral blood mononuclear cells (PBMC) were collected from healthy donors (HD) after informed written consent. Primary WM lymphoplasmacytic cells (LPC) and cell lines were genotyped for MYD88 and CXCR4 mutations as previously described. 2 
Lentiviral transduction experiments
MYD88
WT or MYD88 L265P proteins were over-expressed in BCWM.1 and MWCL-1 cells following lentiviral transduction as previously described. 7 The over- Luminescent measurement was performed using the 2104 Envision® Multilabel
Reader (PerkinElmer Inc.). 
RT-PCR and quantitative-PCR
PhosFlow analysis
PhosFlow analysis was performed to delineate HCK phosphorylation. Cells were 
Immunoblotting
Immunoblotting was performed following gene over-expression, knockdown or kinase pulldown with biotinylated probes using antibodies for HCK, AKT-pT308, AKT, ERK1/2-pT202/pY204, ERK1/2, PLCγ1-pY783, PLCγ2-pY1217, PLCγ2, 
Docking study
The docking studies were performed using AutoDockTools 
Statistical analysis
8
The statistical significance of differences was analyzed using One-way ANOVA with Tukey's multiple comparisons test by Prism software. Differences were considered significant when p<0.05.
Results
HCK transcription is driven by mutated MYD88.
To clarify if HCK expression was aberrant in MYD88 mutated cells, we first Figure 1C ). The results of these studies showed significantly higher levels of HCK transcript in all four cell lines following over-expression of MYD88 L265P versus MYD88 WT protein ( Figure 1C ).
IL6 but not IL6R transcription is induced by mutated MYD88.
Since previous work showed that HCK was activated by IL6 via IL6R/IL6ST, we investigated the regulatory role of mutated MYD88 on IL6 and IL6R expression. 13, 14 By quantitative RT-PCR, IL6 transcription was markedly higher in 
HCK is hyperactive in MYD88 mutated cells, and its activation but not transcription is triggered by IL6.
Given Figure   3D ). Lastly, HCK transcription was not significantly altered following incubation with either IL6 (1-10 ng/mL) or an IL6 blocking antibody (1-10 ug/mL) for two hours in BCWM.1 and MWCL-1 cells using RT-PCR (data not shown).
HCK is a determinant of survival in MYD88 mutated cells
We Kinase selectivity profiling has established that in addition to being a covalent inhibitor of BTK, ibrutinib is also a potent non-covalent inhibitor of several SRC family members including HCK, YES and LCK. 11 We focused our attention on investigating the potential functional significance of HCK to ibrutinib's pharmacology due to its structural similarity with A419259, a HCK inhibitor with established activity in murine tumor models. 16 Indeed both ibrutinib and A419259
were developed based on the 4-amino-5,7-substituted pyrrolopyrimidine scaffold of the classical SRC-family inhibitor: PP1. 26 To create a model for how ibrutinib might bind to HCK we performed a molecular docking studies of ibrutinib into the co-crystal structure of HCK with A419259 (RK-20449) (PDB 3VS3) 27 ( Figure 6A ).
As expected, the docking study predicts that ibrutinib recognizes the ATP-binding 
HCK activity is blocked by ibrutinib and impacts survival of MYD88 mutated WM cells.
To assess the impact of ibrutinib and A419259 on HCK related activity in MYD88 Figure 7A ). Decreased dose-dependent viability was also observed for ibrutinib and more so for A419259 that was more pronounced in mutated MYD88 versus MYD88 WT cells ( Figure 7B ). In contrast, the BTK inhibitor CC-292 that lacks HCK kinase inhibition showed higher EC 50 (>1 log-fold) for the mutated MYD88 cell lines, with the exception of OCI-Ly3 cells that carry a NF-κB activating CARD11 mutation ( Figure 7B ). 5 Increased apoptotic changes were also observed in the mutated MYD88 cell lines and primary WM cells that showed decreased viability following ibrutinib, and more so A419259. In contrast, CC-292 had little or no impact on apoptosis in mutated MYD88 cells ( Figure 7C ). In as well, we observed little or no apoptotic activity for ibrutinib, Figure 7D ).
Discussion
We sought to clarify the contribution of non-BTK target(s) to the activity of ibrutinib in MYD88 mutated diseases such as WM. We focused this study on HCK, a member of the SRC family of kinases. HCK is over-expressed at early stages of B-cell development, and its transcriptional regulation is suppressed with terminal B-cell differentiation. 30, 31 Using gene expression profiling, Guttierez et al 12 previously reported that HCK was highly over-expressed in malignant LPC taken from WM patients, though the genetic basis for this observation remained unclear.
In this study, we observed that HCK was highly expressed in MYD88 mutated The findings also suggest an important role for IL6 in triggering HCK activity in WM, and possibly other MYD88 mutated diseases. We show that both IL6 and IL6R are highly expressed in WM disease, and that MYD88 L265P itself induces IL6 transcription. Ngo et al 5 showed that HCK and IL6 were among 285 genes whose transcription was down-regulated upon knockdown of MYD88 in HBL-1 ABC-DLBCL cells that express L265P as a heterozygous mutation. The role of IL6
as an activator of pHCK through IL6R/IL6ST has previously been reported, and appears dependent on an acidic domain (amino acids 771-811) of IL6ST. 13, 14 IL6 is highly transcribed in WM and ABC-DLBCL tumors. 12, 36, 37 IL6 is also secreted by the bone marrow microenvironment in response to WM cell adhesion. 15 We show in these studies that HCK is hyper-activated in mutated MYD88 primary WM cells, as well as WM and ABC-DLBCL cell lines, and that exogenous IL6 induced its activation while knockdown of IL6ST attenuated HCK activation. HCK was also found to induce PI3K/AKT, MAPK/ERK, and BTK signaling, providing for the first time evidence that mutated MYD88 can trigger pro-survival signaling beyond its known activation of NFKB by eliciting HCK transcription and activation. The transactivation of BTK by HCK is also noteworthy. Cheng et al previously described showed that BTK could bind to HCK through SH3 mediated interactions. In previous work, we described that the activated form BTK was complexed with MYD88 in MYD88 mutated cells, though the mechanism for BTK activation in this context remained unclear. Our findings offer a mechanistic explanation for BTK activation in MYD88 mutated WM and ABC DLCBL cells.
A key finding of this study was the recognition of HCK as a novel therapeutic target for WM, and possibly other mutated MYD88 diseases. Kinase selectivity profiling had previously implicated HCK as a potential target of ibrutinib with an IC 50 of 3.7 nM, a dose level close to the IC 50 of BTK (0.5 nM) and well within the pharmacologically achievable levels of ibrutinib. 11, 38 We provide definitive evidence in this report that HCK is a target of ibrutinib using docking models, ; HCK T338M based on c-SRC numbering) 16 and treated with ibrutinib, A419259 or CC-292. Protein levels following transduction 
